Noom Expands Into Longevity With GLP-1 Microdosing and Biomarker Tracking Program
Krissy Vann | Host, All Things Fitness and Wellness
Noom is moving further beyond weight loss and into preventive health. On December 15, the company announced the launch of a new longevity-focused program that pairs microdoses of GLP-1 medication with behavioral coaching and at-home biomarker testing, signaling a broader shift in how digital health platforms are positioning themselves for long-term health management.
The new offering, called Noom Med with Proactive Health, is designed to address early metabolic risk factors linked to chronic disease rather than focusing solely on weight reduction. The program combines lower-dose GLP-1 prescriptions for eligible members with Noom’s existing behavior-change platform, alongside regular testing of key health markers such as blood sugar, cholesterol, and inflammation.
According to Noom, the goal is to help members intervene earlier, build sustainable habits, and track progress through objective health data rather than relying exclusively on the scale. The company positions the approach as an alternative to higher-dose GLP-1 regimens that are typically prescribed later in the disease cycle.
“Weight loss is often a downstream signal of deeper metabolic issues,” said a Noom spokesperson. “By pairing lower-dose medication with behavior change and biomarker feedback, we believe we can help people take action earlier and support healthier outcomes over time.”
The program reflects a growing trend across the health and fitness landscape, where GLP-1 medications are increasingly being discussed not just as obesity treatments, but as tools within broader longevity and preventive health strategies. Rather than prescribing medication as a standalone solution, Noom’s model integrates coaching, education, and data tracking to reinforce lifestyle changes.
Members enrolled in the program receive ongoing guidance through Noom’s digital platform, which emphasizes habit formation, nutrition education, and accountability. Biomarker testing kits are used to monitor changes over time, giving members and clinicians additional insight into how medication and lifestyle adjustments are affecting overall health.
The launch also underscores how digital health companies are responding to rising consumer interest in longevity, metabolic health, and personalized care. As GLP-1 adoption accelerates, companies like Noom are attempting to differentiate by layering in data, prevention, and long-term engagement rather than focusing solely on rapid weight loss outcomes.
The Proactive Health program is being rolled out in phases, with availability expanding throughout 2026. Noom has not disclosed pricing details but says the program will be offered through its existing medical services infrastructure.
As competition intensifies across the GLP-1 and digital health space, Noom’s move highlights a broader industry shift toward integrating medication, behavior change, and measurable health outcomes into a single care pathway.
